Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy

Trends in Immunology(2023)10.1016/j.it.2023.03.008Source: DataRank Database

T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy is a research paper published in Trends in Immunology (2023). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

3 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.35)OA: closedTopics (30)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Ben Youngblood ORCID,Caitlin C. Zebley ORCID

Live enrichment

PubMed:36959018 OpenAlex:https://openalex.org/W4328053822

National Institutes of Health

Grant: R01CA237311

Alex's Lemonade Stand Foundation for Childhood Cancer

National Comprehensive Cancer Network

Assisi Foundation of Memphis

American Lebanese Syrian Associated Charities

Stand up to Cancer

FWCI

0.35

Citation Percentile

0.6%

Citation Trend

2023

2024

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S1471490623000522?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1471490623000522?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.it.2023.03.008

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36959018

Fields of Study

CAR-T cell therapy researchVirus-based gene therapy researchCRISPR and Genetic Engineering

MeSH Terms

AnimalsDNA-Binding ProteinsImmunotherapyNeoplasmsReceptors, Antigen, T-CellT-LymphocytesImmunotherapy, AdoptiveDioxygenasesMice

Keywords

Chimeric antigen receptorImmunotherapyT cellImmunologyCancer researchCell therapyAntigenCancer immunotherapyEpigeneticsBiologyCAR T-cell therapyCellMedicineImmune systemGeneticsGeneTet2Car T Cells

Sustainable Development Goals

SDG 0: Good health and well-being

T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy

FAIR Checklist

Authors (2)

Funding (6 grants)

Impact

Open Access

Topics